Imatinib
- TRADE NAMES: Gleevec (Novartis); Glivec
- INDICATIONS: Chronic myeloid leukemia
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Biologic, Tyrosine kinase inhibitor
- HALF-LIFE: 18 hours
Acetaminophen, Amlodipine, Anisindione, Anticoagulants, Aprepitant, Atorvastatin, Barbiturates, Benzodiazepines, Butabarbital, Carbamazepine, Chlordiazepoxide, Clarithromycin, Clonazepam, Clorazepate, Corticosteroids, Cyclosporine, Dexamethasone, Diazepam, Dicumarol, Efavirenz, Erythromycin, Ethotoin, Felodipine, Flurazepam, Fluvastatin, Fosphenytoin, Isradipine, Itraconazole, Ketoconazole, Lorazepam, Lovastatin, Mephenytoin, Mephobarbital, Midazolam, Mifepristone, Neratinib, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Olaparib, Oxazepam, Oxcarbazepine, Pentobarbital, Phenobarbital, Phenytoin, Pimozide, Pravastatin, Primidone, Quazepam, Rifampin, Rifapentine, Safinamide, Secobarbital, Simvastatin, St John's Wort, Tafamidis meglumine, Temazepam, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
Investigated for treating COVID-19.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of imatinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/25/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric